Dushyantha Jayaweera

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina et al. · The Lancet · 2007 · 480 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Susanna Naggie, Curtis Cooper, Michael S. Saag et al. · New England Journal of Medicine · 2015 · 467 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

Anthony Mills, Mark Nelson, Dushyantha Jayaweera et al. · AIDS · 2009 · 266 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection

Norah A. Terrault, Michelle E. Roland, Thomas D. Schiano et al. · Liver Transplantation · 2012 · 217 citations

Medicine, Infectious Diseases, Surgery +13